Leukemia

Michael R. Bishop, MD, and Bruce B. Bank, MD, review results from the ELEVATE-RR noninferiority trial on acalabrutinib versus ibrutinib in CLL, and discuss the clinical implications of the findings.

Adult patients with acute myeloid leukemia who are not eligible for treatment with standard induction chemotherapy may benefit from treatment with decitabine and cedazuridine, the marketing authorization application for which was accepted by the European Medicines Agency.

Patients with newly diagnosed acute myeloid leukemia had longer overall survival with a modified dosing schedule of venetoclax plus a hypomethylating agent.

Although European Leukemia Net 2017 Risk Stratification was ineffective for predicting outcomes following allogeneic hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia, pre-transplant Wilms tumor gene 1 expression and FLT3-ITD mutation demonstrated promising predictive ability.

WU-CART-007 was granted fast track and rare pediatric disease designation by the FDA for the treatment of patients with relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

The regulatory organization indicated that duvelisib induces increased risk of death or serious adverse effects in patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

Black adolescent young adult patients with acute myeloid leukemia appeared to have inferior outcomes compared with White patients.

In a new series from CancerNetwork®, 2 teams of fellows from leading institutions go head-to-head to debate the latest datasets and advances in acute lymphoblastic leukemia.

Patients with previously untreated chronic lymphocytic leukemia experienced minimal residual disease negativity following treatment with venetoclax and ibrutinib.

Older patients with acute myeloid leukemia who were treated with decitabine experienced comparable outcomes vs daunorubicin and cytarabine.

Patients with treatment-naïve chronic lymphocytic leukemia who were treated with venetoclax and obinutuzumab with or without ibrutinib experienced a progression-free survival benefit compared with standard chemoimmunotherapy.

The combination of quizartinib plus chemotherapy yielded better survival outcomes vs chemotherapy alone in the frontline setting of FLT3-ITD-positive acute myeloid leukemia.

Findings from the phase 3 ASCEMBL trial indicated that asciminib as a treatment for chronic myelogenous leukemia in chronic phase could represent a new standard of care.

Chances of reaching complete remission and minimal residual disease negativity were greater with the addition of inotuzumab to hyper-CVAD with sequential blinatumomab in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic lymphoma.

Results from the phase 3 AGILE study show patients with IDH1-mutant acute myeloid leukemia had improved outcomes when treated with ivosidenib plus azacitidine vs placebo plus azacitidine.

Combining magrolimab with azacitidine led to manageable anemia in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia.

At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.

Drs Bishop and Bank close by outlining remaining unmet needs in CLL, emerging regimens, and hopes for the future of care.

Michael R. Bishop, MD, and Bruce B. Bank, MD, summarize key takeaways from the ELEVATE-RR study and discuss the clinical implications of using BTK inhibitors in patients with CLL.

Drs Bishop and Bank discuss ELEVATE-RR safety data.

The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.

Xiaoli Mi, MD, presents data from a paper in Blood on the determination of outcomes for adolescents and young adults with ALL.

Varun Narendra, MD, describes a clinical trial that studied whether pediatric-inspired ALL regimens could be used in older adults with Philadelphia chromosome–positive ALL.

Experts discuss use of ponatinib in chronic myeloid leukemia and optimal dosing.

Uday R. Popat, MD, spoke about where he sees future research efforts headed regarding post-transplant cyclophosphamide to prevent graft-vs-host disease for patients with acute myeloid leukemia after transplant and how these results could impact the standard of care.